← All trials

NCT07160244

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
Aug 25, 2025
Primary completion
Nov 6, 2028
Completion date
Mar 2, 2029
First posted
Sep 8, 2025
Last posted
Nov 13, 2025
Enrollment
6000
Arms / groups
7 / —
Source
AACT · ctgov ingestion

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.